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A B S T R A C T
Background
Gestational diabetes is a type of diabetes that occurs during pregnancy. Women with gestational diabetes are more likely to experience
adverse health outcomes such as pre-eclampsia or polyhydramnios (excess amniotic fluid). Their babies are also more likely to have
health complications such as macrosomia (birthweight > 4000 g) and being large-for-gestational age (birthweight above the 90th
percentile for gestational age). Current clinical guidelines support elective birth, at or near term in women with gestational diabetes to
minimise perinatal complications, especially those related to macrosomia.
This review replaces a review previously published in 2001 that included “diabetic pregnant women”, which has now been split into
two reviews. This current review focuses on pregnant women with gestational diabetes and a sister review focuses on women with pre-
existing diabetes (Type 1 or Type 2).
Objectives
To assess the effect of planned birth (either by induction of labour or caesarean birth), at or near term (37 to 40 weeks’ gestation)
compared with an expectant approach for improving health outcomes for women with gestational diabetes and their infants. The
primary outcomes relate to maternal and perinatal mortality and morbidity.
Search methods
We searched Cochrane Pregnancy and Childbirth’s Trials Register, ClinicalTrials.gov and the WHO International Clinical Trials Registry
Platform (ICTRP) (15 August 2017), and reference lists of retrieved studies.
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Selection criteria
We included randomised trials comparing planned birth, at or near term (37 to 40 weeks’ gestation), with an expectant approach, for
women with gestational diabetes. Cluster-randomised and non-randomised trials (e.g. quasi-randomised trials using alternate allocation)
were also eligible for inclusion but none were identified.
Data collection and analysis
Two of the review authors independently assessed study eligibility, extracted data and assessed the risk of bias of the included study.
The quality of the evidence was assessed using the GRADE approach.
Main results
The findings of this review are based on a single trial involving 425 women with gestational diabetes. The trial compared induction
of labour with expectant management (waiting for the spontaneous onset of labour in the absence of any maternal or fetal issues that
may necessitate birth) in pregnant women with gestational diabetes at term. We assessed the overall risk of bias as being low for most
domains, apart from performance, detection and attrition bias (for outcome perineum intact), which we assessed as being at high risk.
It was an open-label trial, and women and healthcare professionals were not blinded.
There were no clear differences between women randomised to induction of labour and women randomised to expectant management
for maternal mortality or serious maternal morbidity (risk ratio (RR) 1.48, 95% confidence interval (CI) 0.25 to 8.76, one trial, 425
women); caesarean section (RR 1.06, 95% CI 0.64 to 1.77, one trial, 425 women); or instrumental vaginal birth (RR 0.81, 95% CI
0.45 to 1.46, one trial, 425 women). For the primary outcome of maternal mortality or serious maternal morbidity, there were no deaths
in either group and serious maternal morbidity related to admissions to intensive care unit. The quality of the evidence contributing
to these outcomes was assessed as very low, mainly due to the study having high risk of bias for some domains and because of the
imprecision of effect estimates.
In relation to primary neonatal outcomes, there were no perinatal deaths in either group. The quality of evidence for this outcome
was judged as very low, mainly due to high risk of bias and imprecision of effect estimates. There were no clear differences in infant
outcomes between women randomised to induction of labour and women randomised to expectant management: shoulder dystocia
(RR 2.96, 95% CI 0.31 to 28.21, one trial, 425 infants, very low-quality evidence); large-for-gestational age (RR 0.53, 95% CI 0.28
to 1.02, one trial, 425 infants, low-quality evidence).
There were no clear differences between women randomised to induction of labour and women randomised to expectant management
for postpartum haemorrhage (RR 1.17, 95% CI 0.53 to 2.54, one trial, 425 women); admission to intensive care unit (RR 1.48,
95% CI 0.25 to 8.76, one trial, 425 women); and intact perineum (RR 1.02, 95% CI 0.73 to 1.43, one trial, 425 women). No
infant experienced a birth trauma, therefore, we could not draw conclusions about the effect of the intervention on the outcomes of
brachial plexus injury and bone fracture at birth. Infants of women in the induction-of-labour group had higher incidences of neonatal
hyperbilirubinaemia (jaundice) when compared to infants of women in the expectant-management group (RR 2.46, 95% CI 1.11 to
5.46, one trial, 425 women).
We found no data on the following prespecified outcomes of this review: postnatal depression, maternal satisfaction, length of postnatal
stay (mother), acidaemia, intracranial haemorrhage, hypoxia ischaemic encephalopathy, small-for-gestational age, length of postnatal
stay (baby) and cost.
The authors of this trial acknowledge that it is underpowered for their primary outcome of caesarean section. The authors of the trial
and of this review note that the CIs demonstrate a wide range, therefore making it inappropriate to draw definite conclusions.
Authors’ conclusions
There is limited evidence to inform implications for practice. The available data are not of high quality and lack power to detect possible
important differences in either benefit or harm. There is an urgent need for high-quality trials evaluating the effectiveness of planned
birth at or near term gestation for women with gestational diabetes compared with an expectant approach.
P L A I N L A N G U A G E S U M M A R Y
Planned birth at or near term for pregnant women with gestational diabetes and their infants
What is the issue?
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The aim of this Cochrane review was to find out if planning an elective birth at or near the term of pregnancy, compared to waiting for
labour to start spontaneously, has an impact on the health of women with gestational diabetes and the health of their babies. Planned
early birth means either induction of labour or caesarean birth, and ’at or near term’ means 37 to 40 weeks’ gestation. To answer this
question, we collected and analysed all relevant studies conducted up to August 2017.
Why is this important?
Women with gestational diabetes (glucose intolerance arising during pregnancy) and their babies are at increased risk of health
complications (e.g. high blood pressure, bigger babies). Because of the complications sometimes associated with birthing a big baby,
many clinicians have recommended that women with gestational diabetes have an elective birth (generally an induction of labour) at
or near term (37 to 40 weeks’ gestation) rather than waiting for labour to start spontaneously, or until 41 weeks’ gestation if all is well.
Induction has disadvantages of increasing the incidence of forceps or ventouse births, and women often find it difficult to cope with
an induced labour. Caesarean section is a major operation which can lead to blood loss, infections and increased chance of problems
with subsequent births. Early birth can increase the chance of breathing problems for babies. It is important to know which approach
to birth has a better impact on the health outcomes of women with gestational diabetes and their babies.
What evidence did we find?
Our search identified one trial involving 425 women and their babies. In this trial, 214 women had an induction of their labour at
term, the other 211 women waited for a spontaneous onset of their labour.
The findings of this trial highlighted no clear difference between the babies of women in either group in relation to the number of
large babies, baby’s shoulder getting stuck during birth or babies with breathing problems, low blood sugar and admission to a neonatal
intensive care unit. No baby in the trial experienced birth trauma. In the group of women whose labour was induced, there were
more incidences of jaundice in the babies. There was no clear difference between women in either group in relation to serious health
problems for women, caesarean section, instrumental vaginal birth, postpartum haemorrhage, admission to an intensive care unit and
intact perineum. There were no reports in either group of maternal deaths. It should be noted that most of the evidence was found to
be of very low quality.
The following outcomes were not reported: postnatal depression, maternal satisfaction, length of postnatal stay (mother), babies with
high blood acid, bleeding in the baby’s brain, other brain problems for the babies, babies small-for-gestational age and length of baby’s
postnatal stay.
What does this mean?
There is insufficient evidence to clearly identify if there are differences in health outcomes for women with gestational diabetes and
their babies when elective birth is undertaken compared to waiting for labour to start spontaneously or until 41 weeks’ gestation if all
is well. More research is needed to answer this question.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Planned birth (induction or caesarean) compared to expectant management for pregnant women with gestational diabetes
Patient or population: pregnant women with gestat ional diabetes, between 38 - 39 gestat ional weeks, without other maternal or fetal condit ions.
Setting: Italy, Slovenia and Israel.
Intervention: planned birth (induct ion of labour at 38/ 39 gestat ional weeks).
Comparison: expectant management of labour.
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sured
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*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 One study included in this review, therefore inconsistency cannot be assessed
2 High risk of bias for blinding of part icipants and personnel and blinding of outcome assessment (downgraded x 1)
3 Conf idence interval crosses the line of no ef fect and conf idence intervals include appreciable benef it and harm. Criteria
for opt imal information size (23,171 women per group), in relat ion to intensive care unit admission, have not been met
(downgraded x 2).
4 Conf idence interval crosses the line of no ef fect and conf idence intervals include appreciable benef it and harm. Criteria for
opt imal information size (1,616 women per group) have not been met (downgraded x 2).
5 Conf idence interval crosses the line of no ef fect and conf idence intervals include appreciable benef it and harm. Criteria for
opt imal information size (1,920 women per group) have not been met (downgraded x 2).
6 No events for this outcome. Drawing on the neonatal deaths recorded in Rosenstein 2012 at 37, 38 and 39 weeks’ gestat ion
for women with gestat ional diabetes, criteria for opt imal information size (477,500 women per group) have not been met
(downgraded x 2).
7 Conf idence interval crosses the line of no ef fect and conf idence intervals include appreciable benef it and harm. Criteria for
opt imal information size (46,145 women per group) have not been met (downgraded x 2).
8 Conf idence interval crosses the line of no ef fect and conf idence intervals include appreciable benef it . Criteria for opt imal









































































































































B A C K G R O U N D
A planned birth has been advocated in the setting of an otherwise
low-risk singleton pregnancy after 41 weeks (Gulmezoglu 2012);
by some healthcare professionals at 37 to 40 weeks of pregnancy
where suspicion of macrosomia exists (Boulvain 2016); and for
women with an uncomplicated twin pregnancy at 37 weeks’ ges-
tation (Dodd 2014). The aim of such an intervention is to reduce
adverse pregnancy outcomes associated with these scenarios. Sys-
tematic reviews show that induction of labour after 41 weeks is the
only intervention associated with a reduction in perinatal mortal-
ity (Gulmezoglu 2012). In the area of pregnancy-related diabetes,
a previously published Cochrane review concluded that elective
birth at term in pregnant women with insulin-requiring diabetes
reduces the risk of macrosomia but does not impact on maternal
or neonatal morbidity (Boulvain 2001). While most women in
this prior review had gestational diabetes, it also included several
women with pre-existing Type 2 diabetes.
The original Cochrane review ’Elective delivery in diabetic preg-
nant women’ (Boulvain 2001) has now been split into the follow-
ing two reviews.
1. Planned birth at or near term for improving health
outcomes for pregnant women with gestational diabetes and
their infants (this review).
2. Planned birth at or near term for improving health
outcomes for pregnant women with pre-existing diabetes and
their infants (Biesty 2017a).
As gestational diabetes is typically a transient glucose abnormality
occurring late in the second trimester of pregnancy, whilst pre-
existing diabetes exists throughout the entire pregnancy, it is im-
portant to clearly differentiate between these different conditions
when approaching the issue of planned birth. It is acknowledged
that there will be similarities in the background, methods and out-
comes between these two systematic reviews.
Description of the condition
Gestational diabetes is defined as carbohydrate intolerance result-
ing in hyperglycaemia (high blood sugar) of variable severity, with
onset or first recognition during pregnancy (WHO 2014). The
diagnosis excludes those with diabetes in pregnancy which is likely
to represent overt or pre-existing diabetes. The worldwide preva-
lence of gestational diabetes varies significantly, but rates are clearly
rising in parallel with increasing rates of Type 2 diabetes and obe-
sity (Bottalico 2007). While prevalence is most often reported as
2% to 6% of pregnancies, rates of over 20% are cited in selected
populations (Buckley 2012); however, inconsistencies in screen-
ing and diagnostic criteria reduce the accuracy of prevalence data
(Avalos 2013; Benhalima 2015). A recently published Cochrane
review has concluded that there is insufficient evidence to suggest
which strategy is best for diagnosing gestational diabetes (Farrar
2017).
Women with gestational diabetes have increased insulin resis-
tance; this can lead to maternal hyperglycaemia and increased glu-
cose transport across the placenta, with resultant fetal hyperin-
sulinaemia (higher-than-normal levels of insulin) and accelerated
growth (Setji 2005). Gestational diabetes is associated with an
elevated risk of complications during pregnancy including pre-
eclampsia, polyhydramnios (excess amniotic fluid) and the need
for caesarean birth (Reece 2010; O’Sullivan 2012). While gesta-
tional diabetes typically resolves after the pregnancy, it is associ-
ated with an increased lifetime risk of maternal Type 2 diabetes
(O’Sullivan 1980; Metzger 1985; O’Dea 2015; Noctor 2016). In-
fants born to mothers with gestational diabetes are more likely
to be macrosomic (birthweight > 4000 g) or large-for-gestational
age (birthweight above the 90th percentile for gestational age)
(Crowther 2005; Metzger 2008; Reece 2010). These infants are
at increased risk of birth injury and later-life Type 2 diabetes and
metabolic syndrome (Reece 2010). Additional infant complica-
tions include neonatal hypoglycaemia (low blood sugar), respira-
tory complications and admission to a neonatal intensive care unit
(Ramos-Roman 2011; Kgosidialwa 2015).
During the second and early third trimesters, physiological in-
sulin resistance increases to facilitate glucose transfer across the pla-
centa to the fetus, and ensure adequate growth and development
(Farrar 2016). This insulin-resistant state is created by placental
hormones including oestrogen, progesterone, cortisol, placental
lactogen, prolactin and growth hormone (Setji 2005). The mater-
nal pancreas compensates for this pregnancy-induced insulin re-
sistance by secreting more insulin (Wilcox 2005; McCurdy 2010).
In gestational diabetes, more severe insulin resistance is accompa-
nied by insufficient release of compensatory insulin, which limits
the transport of glucose into cells and increases maternal glucose
concentration (Setji 2005). This results in hyperglycaemia in the
developing fetus, stimulating fetal insulin production and leading
to over-nourishment of the fetus (Tieu 2008). In recent times, it
is becoming evident that additional factors such as alterations in
lipid metabolism and inflammatory change may also contribute
to the abnormal metabolic environment associated with pregnan-
cies complicated by diabetes, particularly when obesity co-exists
(Catalano 2011).
Gestational diabetes is associated with complications for the in-
fant including fetal macrosomia, being large-for-gestational age,
and increased need for admission to a neonatal intensive care unit
(O’Sullivan 2012; Wendland 2012; Kgosidialwa 2015). A strong
emphasis is placed on the association with macrosomia because of
consequences such as shoulder dystocia (baby’s shoulder getting
stuck during birth) and other birth injuries (Tieu 2008; Reece
2010). One systematic review concluded that after the index preg-
nancy, the cumulative incidence of diabetes ranged from 2.6% to
70% in studies that examined women 6 weeks to 28 years post-
partum (Kim 2002). Predictive factors for developing abnormal
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glucose tolerance after gestational diabetes include glucose levels
on the pregnancy oral glucose tolerance test, a family history of
diabetes and body mass index at follow-up (Noctor 2016). In the
long-term, offspring of women with gestational diabetes are at in-
creased risk of obesity, pre-diabetes, diabetes and neurosensory dis-
abilities including autism spectrum disorders (Krakowiak 2012;
Page 2014).
There is a wide range of maternal risk factors associated with
the development of gestational diabetes, including maternal obe-
sity, increased maternal age, family history of Type 2 diabetes,
and having gestational diabetes or macrosomia in a previous preg-
nancy (Aktun 2015; Chen 2015; Duman 2015; Jafari-Shobeiri
2015). Certain ethnicities including Asian, African American, Na-
tive American, Hispanic and Pacific Island also have an increased
risk of developing gestational diabetes (Carolan 2012; Schneider
2012; Chamberlain 2013; Kim 2013). Despite the large numbers
at risk of gestational diabetes, the optimal screening approach is
under dispute. Some groups, including the American Diabetes As-
sociation (ADA) and the International Association of Diabetes and
Pregnancy Study Groups (IADPSG), advocate universal screening
using a diagnostic test (75 g oral glucose tolerance test), whereas
others, including the National Institute for Health and Care Ex-
cellence (NICE) in the UK, recommend risk-factor based screen-
ing (Metzger 2010; NICE 2015; Benhalima 2016; ADA 2017). It
must be noted that a significant number of women have no clas-
sical risk factors for gestational diabetes, and women falling into
this category who were diagnosed on the basis of universal screen-
ing experience more adverse pregnancy outcomes than those with
normal glucose tolerance (Avalos 2013).
Similar to screening, the diagnosis of gestational diabetes is con-
troversial. The condition is identified by a diagnostic oral glu-
cose tolerance test; however, the amount of glucose recommended
for this test differs (75 g to 100 g) and there is significant varia-
tion in postprandial glucose concentrations (blood sugar levels af-
ter eating) above which gestational diabetes is diagnosed (ACOG
2013; New Zealand Ministry of Health 2014; WHO 2014; NICE
2015). To illustrate further, in 2008 the International Association
of Diabetes and Pregnancy Study Groups (IADPSG) developed
a consensus statement for a new strategy to diagnose gestational
diabetes based on the results of the Hyperglycaemia and Neonatal
Outcomes (HAPO) study (Metzger 2008; Metzger 2010). The
thresholds for diagnosis chosen, by the IADPSG, are the average
glucose values at which odds for birthweight > 90th percentile,
cord C-peptide > 90th percentile and percent body fat > 90th per-
centile reached 1.75 times the estimated odds of these outcomes
at mean glucose levels (IADPSG Consensus Panel 2010). These
guidelines were subsequently endorsed by the World Health Or-
ganization (WHO), The Endocrine Society and the International
Federation of Gynecology and Obstetrics (FIGO) (Blumer 2013;
WHO 2014; Hod 2015). However, for a variety of reasons, in-
cluding health economic analysis and treatment effects from in-
tervention trials, these recommendations have not been adopted
universally (Bilous 2015; NICE 2015). Finally, while gestational
diabetes is typically diagnosed between 24 and 28 weeks’ gesta-
tion, earlier assessment is often advised for women considered to
be high-risk (Setji 2005). Unfortunately, there are no randomised
controlled trial data examining the balance between the additional
benefits and the cost of detecting and treating women diagnosed
with gestational diabetes (excluding those with overt diabetes) in
early pregnancy (McIntyre 2016).
Description of the intervention
Following diagnosis, the primary aims of treatment for gestational
diabetes are to optimise glycaemic control and improve pregnancy
outcomes (Brown 2016; Brown 2017a; Brown 2017b). Women
are typically treated with diet and lifestyle advice along with self-
monitoring of glucose to ensure tight glycaemic goals are achieved
(NICE 2015). If these interventions cannot limit maternal hyper-
glycaemia, pharmacological therapy is introduced. Increased ob-
stetric monitoring, including more frequent antenatal visits and
regular ultrasound monitoring, is typically employed to monitor
fetal growth and other potential comorbidities in women with ges-
tational diabetes. In the United Kingdom, the NICE guidelines
advise women with gestational diabetes to birth no later than 40+6
weeks’ (40 weeks plus six days’) gestation and to consider elective
birth before 40+6 weeks if there are maternal or fetal complica-
tions (NICE 2015). Guidelines issued by the Americian College
of Obstetricians and Gynecologists (ACOG) in July 2017 suggest
that women with gestational diabetes treated with diet and lifestyle
advice should be offered expectant management up to 40+6 weeks’
gestation; women on medications who are achieving their gly-
caemic goals should birth between 39 and 39+6 weeks’ gestation;
and women with “poorly controlled” glycaemic goals should birth
between 37 and 38+6 weeks’ gestation (ACOG 2017).
A woman’s pregnancy is considered to be ’at term’ when her preg-
nancy duration reaches 37 weeks (Gulmezoglu 2012). Planned
birth involves the early birth of the infant either by induction of
labour or by caesarean section. This typically takes place between
37 and 40 weeks’ gestation. Methods of induction vary accord-
ing to local protocols and typically depend on cervical status. The
process generally involves cervical ripening with misoprostol or
prostaglandin E2 (PGE2) followed by amniotomy (the artificial
rupture of membranes) and oxytocin infusion if labour has not
started (Boulvain 2016). The alternative is the expectant approach
to the management of birth, which refers to waiting for the spon-
taneous onset of labour in the absence of any maternal or fetal
issues that may necessitate birth (Bond 2017).
How the intervention might work
In women with gestational diabetes, the rationale for performing
an elective birth includes possible reduction in perinatal compli-
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cations, especially those related to macrosomia (Brudenell 1989).
Macrosomia is typically defined as a birthweight of more than
4000 g (Feig 2015). It is associated with an increased chance of
prolonged labour, maternal trauma, emergency caesarean birth
and a higher risk of birth injuries for the infant, including clavicle
fracture and brachial plexus injury (Perlow 1996; Ju 2009). How-
ever, for some women and babies the birth can be straightforward.
A recent Cochrane review of induction of labour at or near term
for suspected fetal macrosomia (Boulvain 2016) concluded that
further trials are necessary to clarify if the benefits, including lower
mean birthweight and fewer instances of birth fracture and shoul-
der dystocia, outweigh the risks which include increased perineal
damage.
Why it is important to do this review
In 1989, the St Vincent declaration called on governments and
healthcare services to implement effective measures to achieve
pregnancy outcomes in women with diabetes that approximate
those of women without diabetes within five years (St Vincent
Declaration 1990). While this goal was not achieved, it is impor-
tant that we strive to identify any measures that may assist in meet-
ing this target in our care for the increasing numbers of women
with gestational diabetes. Planned births may have potential ben-
efits, possibly reducing the risks of prolonged labour and elevated
rates of caesarean section following induction of labour (Macer
1992). Birth by caesarean section, including elective caesarean,
may increase the risk of maternal morbidity including postpar-
tum infections, haemorrhage or uterine rupture during subsequent
labour (Irion 1998). Induction of labour may lead to increased
interventions during labour and birth and an increase in maternal
morbidity (Khireddine 2013). Furthermore, early-term birth is
associated with an increased risk of multiple neonatal morbidities
including respiratory distress syndrome and the need for mechan-
ical ventilation and admission to a neonatal intensive care unit
(ACOG 2013). Women’s views on elective birth versus contin-
ued antenatal surveillance should also be considered (Dodd 2014).
The existing Cochrane review on this topic, ‘Elective delivery in
diabetic pregnant women’ (Boulvain 2001) includes women with
insulin-treated diabetes who had a diagnosis of gestational dia-
betes or Type 2 diabetes, and does not examine women with ges-
tational diabetes treated with non-pharmacological interventions
alone. Furthermore, this review was published in 2001 and it is
possible that additional evidence on this subject is now available
for analysis.
Based on the above, it is now important to assess the effect of a
policy of planned birth compared with an expectant approach on
maternal and perinatal mortality and morbidity in women with
gestational diabetes. Women and healthcare professionals need
unbiased information on this subject and this is best provided by
meta-analysis of high-quality randomised controlled trials.
O B J E C T I V E S
To assess the effect of planned birth (either by induction of labour
or caesarean birth), at or near term (37 to 40 weeks’ gestation)
compared with an expectant approach for improving health out-
comes for women with gestational diabetes and their infants. The
primary outcomes relate to maternal and perinatal mortality and
morbidity.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all published randomised trials (including those us-
ing a cluster-randomised design) and non-randomised trials which
compared planned birth at or near term gestation, with an ex-
pectant approach for women with gestational diabetes. Non-ran-
domised trials are trials in which participants are allocated to treat-
ment groups using non-random methods (e.g. alternate) (EPOC
2016).
Cross-over studies were excluded as this design is not appropriate
for this intervention.
Studies published in abstract form were only eligible for inclusion
where information on risk of bias and primary or secondary out-
comes could be obtained.
Types of participants
Pregnant women, at or near term gestation (37 to 40 weeks’ ges-
tation), with gestational diabetes as diagnosed according to each
included study.
Pregnant women with pre-existing diabetes will be included in a
different Cochrane review, titled ’Planned birth at or near term for
improving health outcomes for pregnant women with pre-existing
diabetes and their infants’ (Biesty 2017a).
We planned to exclude trials that included women both with ges-
tational diabetes and pre-existing diabetes where data could not
be separated.
Types of interventions
Planned birth (induction of labour or caesarean section) at or near
term gestation.
Induction of labour was defined by trial authors and may include
the use of prostaglandins, misoprostol, oxytocin, amniotomy or a
combination of these.
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Comparisons
1. Planned birth at or near term gestation versus an expectant
approach
An expectant approach to the management of birth refers to wait-
ing for the spontaneous onset of labour in the absence of any ma-
ternal of fetal issues that may necessitate birth (Bond 2017) (or
until 41 weeks’ gestation or more, when induction of labour may
be offered).
Types of outcome measures
For this review, we adapted the core outcome set agreed by con-
sensus between review authors of the Cochrane Pregnancy and
Childbirth systematic reviews for prevention and treatment of ges-
tational diabetes and pre-existing diabetes. The core outcome set
was adapted to ensure that the outcome measures included were
appropriate for this research question.
Primary outcomes
Maternal
1. Maternal mortality or serious maternal morbidity (i.e.
cardiac arrest, respiratory arrest, admission to intensive care unit
(ICU))
2. Caesarean section
3. Instrumental vaginal birth (forceps or vacuum)
Neonatal
1. Perinatal mortality rate (corrected, i.e. stillbirths and
neonatal deaths excluding lethal congenital anomalies)
2. Shoulder dystocia
3. Large-for-gestational age (birthweight greater than the 90th
centile or as defined by the trial authors)
4. Acidaemia (as evident by a pH of less than 7.0 or a base
deficit greater than 12 mmol/L in umbilical arterial cord blood
or neonatal blood sample within the first hour of life, or both)
Where available, all primary outcomes were included in a ’Sum-






4. Admission to ICU
5. Intact perineum
6. Uterine rupture
7. Postpartum haemorrhage (defined as 1000 mL or more)
8. Postnatal depression (as measured by either the Edinburgh
Postnatal Depression Scale, the Postpartum Depression
Screening Scale, the Beck Depression Inventory or other
validated scales)
9. Maternal satisfaction (as measured by trial authors)
Neonatal
1. Brachial plexus injury
2. Bone fracture at birth
3. Intracranial haemorrhage (all grades)
4. Hypoxic ischaemic encephalopathy
5. Respiratory distress syndrome
6. Neonatal hypoglycaemia (blood glucose concentrations
below the normal range, investigator defined)
7. Neonatal hyperbilirubinaemia (blood bilirubin
concentrations above the normal range, investigator defined)
8. Small-for-gestational age (birthweight below the third
centile or as defined by the trial authors)
9. Admission to neonatal ICU
10. Neurosensory disability (defined by a standardised
assessment tool at approximately two years of age)
Health service outcomes
1. Length of postnatal stay (mother)
2. Length of postnatal stay (baby)
3. Cost
Search methods for identification of studies
The following methods section of this review is based on a standard
template used by Cochrane Pregnancy and Childbirth.
Electronic searches
We searched Cochrane Pregnancy and Childbirth’s Trials Register
by contacting their Information Specialist (15 August 2017).
The Register is a database containing over 23,000 reports of con-
trolled trials in the field of pregnancy and childbirth. For full search
methods used to populate Pregnancy and Childbirth’s Trials Regis-
ter, including the detailed search strategies for CENTRAL, MED-
LINE, Embase and CINAHL; the list of handsearched journals
and conference proceedings; and the list of journals reviewed via
the current awareness service, please follow this link to the edi-
torial information about Cochrane Pregnancy and Childbirth in
the Cochrane Library and select the ’Specialized Register’ section
from the options on the left side of the screen.
Briefly, Cochrane Pregnancy and Childbirth’s Trials Register is
maintained by their Information Specialist and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
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2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Two people screen the search results and review the full text of
all relevant trial reports identified through the searching activities
described above. Based on the intervention described, each trial re-
port is assigned a number that corresponds to a specific Pregnancy
and Childbirth review topic (or topics), and is then added to the
Register. The Information Specialist searches the Register for each
review using this topic number rather than keywords. This results
in a more specific search set that has been fully accounted for in
the relevant review sections (Included studies; Excluded studies;
Studies awaiting classification).
In addition, we searched ClinicalTrials.gov and the WHO Inter-
national Clinical Trials Registry Platform (ICTRP) (15 August
2017) for unpublished, planned and ongoing trial reports using
the search methods detailed in Appendix 1.
Searching other resources
We searched the reference lists of retrieved studies.
We did not apply any language or date restrictions.
Data collection and analysis
We designed a form to extract data. Two review authors (LB and
DD) independently extracted the data from eligible studies using
the agreed form. We did not have any disagreements but if we had,
we would have resolved these through discussion or, if required,
through consultation with a third person. We pilot tested the data
extraction tool on one related, but not included, paper prior to
conducting the full review and amended the form as necessary.
Where additional information was needed, we contacted the au-
thors of the original report to provide further details and have
noted this contact in Characteristics of included studies.
Selection of studies
Two review authors independently assessed for inclusion all poten-
tially eligible studies identified by our search strategy. We planned
to resolve any disagreement through discussion or by consulting a
third person if necessary.
We created a study flow diagram to map out the number of records
identified, included and excluded (Figure 1).
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Figure 1. Study flow diagram.
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Data extraction and management
We designed a form to extract data. For eligible studies, two review
authors extracted the data independently using the agreed form.
We did not have any disagreements but if we had, we would have
resolved discrepancies through discussion or, if required, through
consultation with a third person. We pilot tested the data extrac-
tion tool on one related, but not included, paper prior to conduct-
ing the full review and amended the form as necessary. LB entered
all data into Review Manager 5 (RevMan 5) software (RevMan
2014) which was checked for accuracy by DD.
Where additional information was needed, we contacted the au-
thors of the original report to provide further details and have
noted this contact in Characteristics of included studies.
Assessment of risk of bias in included studies
Two review authors (LB and DD) independently assessed the risk
of bias in each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We had no disagreements but if we had, we would have resolved
these through discussion or by consultation with a third person if
necessary.
We did not identify any cluster-randomised trials. Had we done
so, we would have used appropriate methods for assessing bias in
these designs as outlined in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011).
Where information on risk of bias relates to unpublished data or
correspondence with trialists, this is noted in the ’Risk of bias’
table.
(1) Random sequence generation (checking for possible
selection bias)
We described the method used to generate the allocation sequence
in sufficient detail to allow an assessment of whether it should
produce comparable groups.
For each included study we assessed the method as being at:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
For each included study we described the method used to con-
ceal allocation to interventions prior to assignment and assessed
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We assessed the methods as being at:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes; alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
For each included study we described the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered that studies
were at low risk of bias if they were blinded, or if we judged that
the lack of blinding was unlikely to affect results.
We assessed the methods as being at:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
For each included study we described the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received.
We assessed methods used to blind outcome assessment as being
at low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
For each included study, and for each outcome or class of out-
comes, we described the completeness of data including attrition
and exclusions from the analysis. We stated whether attrition and
exclusions were reported and the numbers included in the analysis
at each stage (compared with the total randomised participants),
reasons for attrition or exclusion where reported, and whether
missing data were balanced across groups or were related to out-
comes. Where sufficient information was reported, or could be
supplied by the trial authors, we planned to re-include missing
data in the analyses that we undertook.
We assessed methods as being at:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups; the proportion of missing
data was less than the effect size, and so unlikely to overturn the
study result);
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• high risk of bias (i.e. where attrition is 20% or more for
outcomes or groups of outcomes). We explored if number or
reasons for missing data were balanced across groups);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
For each included study we described how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as being at:
• low risk of bias (where it was clear that all of the study’s
prespecified outcomes and all expected outcomes of interest to
the review have been reported);
• high risk of bias (where not all the study’s prespecified
outcomes were reported; one or more reported primary
outcomes were not prespecified; outcomes of interest were
reported incompletely and so could not be used; study failed to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
For each included study we described any important concerns we
had about other possible sources of bias.
(7) Overall risk of bias
We made explicit judgements about whether studies were at high
risk of bias, according to the criteria given in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011). With
reference to (1) to (6) above, we planned to assess the likely mag-
nitude and direction of the bias and whether we considered it was
likely to have an impact on the findings. In future updates, we
will explore the impact of the level of bias through undertaking
Sensitivity analysis.
Assessment of the quality of the evidence using the
GRADE approach
We used the GRADE approach as outlined in the GRADE
handbook to assess the quality of the body of evidence relating to
the following outcomes for the comparisons of planned birth (in-
duction of labour or caesarean section), at or near term gestation
versus an expectant approach.
1. Maternal mortality or serious maternal morbidity (e.g.
cardiac arrest, respiratory arrest, admission to ICU)
2. Caesarean section
3. Instrumental vaginal birth (forceps or vacuum)
4. Perinatal mortality rate (corrected, i.e. stillbirths and
neonatal deaths excluding lethal congenital anomalies)
5. Shoulder dystocia
6. Large-for-gestational age (birthweight greater than the 90th
centile or as defined by the trial authors)
7. Acidaemia (as evident by a pH of less than 7.0, or a base
deficit greater than 12 mmol/L in umbilical arterial cord blood
or neonatal blood sample within the first hour of life, or both)
We used GRADEpro Guideline Development Tool software to
import data from RevMan 5 and create ’Summary of findings’
tables. A summary of the intervention effect and a measure of
quality for each of the above outcomes was produced using the
GRADE approach. The GRADE approach uses five considera-
tions (study limitations, consistency of effect, imprecision, indi-
rectness and publication bias) to assess the quality of the body of
evidence for each outcome. The evidence can be downgraded from
’high quality’ by one level for serious limitations (or by two levels
for very serious limitations) depending on assessments for risk of
bias, indirectness of evidence, serious inconsistency, imprecision
of effect estimates or potential publication bias.
Measures of treatment effect
Dichotomous data
For dichotomous data, we present results as summary risk ratios
with 95% confidence intervals.
Continuous data
We did not find any continuous data but should we find such data
in future updates of the review, we will use the mean difference if
outcomes are measured in the same way between trials. We will
use the standardised mean difference to combine data from trials
that measure the same outcome, but use different methods.
Unit of analysis issues
Cluster-randomised trials
We did not find any cluster-randomised trials. Had we done so we
would have considered them for inclusion in the analyses along
with individually randomised trials. In future updates of this re-
view, we will consider including cluster trials and will adjust their
sample sizes using the methods described in Cochrane Handbook
(Higgins 2011) using an estimate of the intracluster correlation co-
efficient (ICC) derived from the trial (if possible), from a similar
trial, or from a study of a similar population. If we use ICCs from
other sources, we will report this and conduct sensitivity analyses
to investigate the effect of variation in the ICC. If we identify both
cluster-randomised trials and individually-randomised trials, we
plan to synthesise the relevant information. We will consider it
reasonable to combine the results from both if there is little het-
erogeneity between the study designs and the interaction between
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the effect of intervention and the choice of randomisation unit is
unlikely.
We will also acknowledge heterogeneity in the randomisation unit
and perform a sensitivity analysis to investigate the effects of the
randomisation unit.
Studies with multiple arms
We did not find any studies with multiple arms. In future updates,
for studies with multiple treatment arms, we will combine all rel-
evant experimental intervention groups in the study (e.g. groups
with different methods for induction of labour) into a single group,
and combine all comparable relevant control intervention groups
into a single control group and perform a single pair-wise compar-
ison, as recommended in the Cochrane Handbook (Higgins 2011).
Dealing with missing data
For included studies, we noted levels of attrition. We had planned
to explore the impact of including studies with high levels of miss-
ing data in the overall assessment of treatment effect by using sen-
sitivity analysis but this was not possible because of inclusion of
only one study.
For all outcomes, we carried out analyses, as far as possible, on
an intention-to-treat basis, i.e. we included all participants ran-
domised to each group in the analyses, and all participants were
analysed in the group to which they were allocated, regardless of
whether they received the allocated intervention. The denomina-
tor for each outcome in each trial was the number randomised
minus any participants whose outcomes are known to be missing.
Assessment of heterogeneity
Because we could only include one study, there was no heterogene-
ity to assess. In future updates, we will assess statistical heterogene-
ity in each meta-analysis using the Tau2, I2 and Chi2 statistics. We
will regard heterogeneity as substantial if I2 is greater than 30%
and either Tau2 is greater than zero, or there is a low P value (less
than 0.10) in the Chi2 test for heterogeneity.
Assessment of reporting biases
Because we could only include one study, we did not assess report-
ing biases. In future updates, if there are 10 or more studies in the
meta-analysis we will investigate reporting biases (such as publica-
tion bias) using funnel plots. We will assess funnel plot asymmetry
visually. If asymmetry is suggested by a visual assessment, we will
perform exploratory analyses to investigate it.
Data synthesis
We carried out statistical analysis using the RevMan 5 (RevMan
2014). We did not conduct a meta-analysis. In future updates,
we will use fixed-effect meta-analysis for combining data where it
is reasonable to assume that studies are estimating the same un-
derlying treatment effect, i.e. where trials are examining the same
intervention, and the trials’ populations and methods are judged
sufficiently similar. If there is clinical heterogeneity sufficient to
expect that the underlying treatment effects differ between trials,
or if substantial statistical heterogeneity is detected, we will use
random-effects meta-analysis to produce an overall summary if an
average treatment effect across trials is considered clinically mean-
ingful. The random-effects summary will be treated as the average
of the range of possible treatment effects and we will discuss the
clinical implications of treatment effects differing between trials.
If the average treatment effect is not clinically meaningful we will
not combine trials.
If we use random-effects analyses, the results will be presented as
the average treatment effect with 95% confidence intervals, and
the estimates of Tau2 and I2.
Subgroup analysis and investigation of heterogeneity
We had planned to investigate substantial heterogeneity using sub-
group analyses and sensitivity analyses, but were unable to do so
due to there being only one included study. In future updates we
will explore heterogeneity and consider whether an overall sum-
mary is meaningful, and if it is, we will use random-effects analysis
to produce it.
In future updates, we plan to carry out the following subgroup
analyses.
1. Parity: primiparous women versus multiparous women
2. Birth by planned caesarean section versus planned
induction of labour
The following outcomes will be used in subgroup analysis.
Maternal
1. Maternal mortality or serious maternal morbidity (e.g.
cardiac arrest, respiratory arrest, admission to ICU)
2. Caesarean section
3. Instrumental vaginal birth (forceps or vacuum)
Neonatal
1. Corrected perinatal mortality rate (stillbirth and early
neonatal deaths, excluding lethal congenital anomalies)
2. Shoulder dystocia
3. Large-for-gestational age (birthweight greater than the 90th
centile or as defined by the trial authors)
4. Acidaemia (as evident by a pH of less than 7.0, or a base
deficit greater than 12 mmol/L in umbilical arterial cord blood
or neonatal blood sample within the first hour of life, or both.
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We will assess subgroup differences by interaction tests available
within RevMan 5 (RevMan 2014). We will report the results of
subgroup analyses quoting the Chi2 statistic and P value, and the
interaction test I2 value.
Sensitivity analysis
We had planned to conduct a sensitivity analysis on risk of bias in
trials by excluding all studies at high or unclear risk of bias for either
sequence generation or allocation concealment, based on growing
empirical evidence that these factors are particularly important
potential sources of bias (Higgins 2011). We had also planned to
limit sensitivity analyses to primary outcomes. However, because
we included only one study, it was not possible to conduct this
sensitivity analysis. In future updates, we will perform this analysis
if possible.
R E S U L T S
Description of studies
Results of the search
See: Figure 1.
Our search strategy identified 64 citations. After screening, we re-
trieved 10 reports of six trials for potential inclusion. Of those, one
trial that included a total of 425 women was included (Alberico
2017; see Characteristics of included studies). We are awaiting
the classification of two trials (Henry 1992; Dhaneshwor 2011
(CTRI/2011/12/002290)) see Characteristics of studies awaiting
classification). Three trials (Khojandi 1974; Ghosh 1979; Worda
2017) were excluded (see Characteristics of excluded studies).
Included studies
Design
The included study (Alberico 2017) was a multi-centre open-la-
belled randomised controlled trial.
Sample sizes
Four-hundred and twenty-five women participated in the trial
(Alberico 2017).
Setting
The multi-centre trial occurred in eight ’centres’ in three countries
(Italy, Slovenia and Israel). Recruitment took place from March
2010 to March 2014.
Participants
In total, 425 women were randomised (n = 214 intervention arm,
n = 211 control arm). Inclusion criteria were: pregnant women,
older than 18, with singleton pregnancy, vertex presentation and
diagnoses of gestational diabetes in this pregnancy. Women were
excluded if they had a diagnosis of overt diabetes, prior caesarean
section, obstetrical contraindications to vaginal birth, maternal
pregnancy-related disease or non-reassuring fetal well-being ne-
cessitating prompt birth, uncertain gestational age, known fetal
anomaly, Bishop score less than seven, or estimated fetal weight of
4000 g at enrolment (between 38+0 and 39+0 gestational weeks).
Interventions and comparisons
Women allocated to the to the induction of labour group (n = 214)
were admitted to “the ward” between 38+0 and 39+0 gestational
weeks and induction of labour was performed using dinoprostone
(2 mg vaginally) or dinoprostone (0.5 mg intracervically) in six-
to eight-hour intervals (up to five doses), or a dinoprostone (10
mg) vaginal device. Once a woman’s Bishop score exceeded seven,
or regular contractions were diagnosed, women were transferred
to the delivery ward for an artificial rupture of membranes or
oxytocin augmentation. Women for whom cervical ripening did
not occur (Bishop score less than seven) after five attempts with
prostaglandin E2, were offered either oxytocin or Foley catheter in-
duction or caesarean section. Women allocated to expectant man-
agement (n = 211) were followed up twice weekly from 38+0 or 39
+0 gestational weeks. Twice weekly they had “electronic fetal heart
rate monitoring and a biophysical profile”. The authors define this
as “intensive follow up”. At 41 gestational weeks, women were
offered an induction of labour.
Outcomes
Outcomes considered in the review and reported in or extracted
from the study included: maternal mortality rate, serious maternal
morbidity, caesarean section, instrumental birth, intact perineum,
postpartum haemorrhage, admission to intensive care unit, peri-
natal mortality rate, shoulder dystocia, large-for-gestational age,
birth trauma, respiratory distress syndrome, neonatal hypogly-
caemia, neonatal hyperbilirubinaemia and admission to neonatal
intensive care unit.
Funding
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The Institute for Maternal & Child Health, IRCCS, Burlo Garo-
folo “offered human and financial resources to carry out the
project”. Trial authors’ declaration of interest: none declared.
Excluded studies
We excluded three studies: Ghosh 1979; Khojandi 1974 and
Worda 2017 (see Characteristics of excluded studies). Ghosh
1979 was excluded as this study focused on women with “Type
B diabetes” (Type 2) and no further details or publications have
been made available in relation to this study since the publication
of the conference abstract 38 years ago. We excluded Khojandi
1974 because insufficient information was provided to determine
randomisation in this study (given that the study was published
42 years ago, we did not attempt to contact the authors). We ex-
cluded Worda 2017 as this trial randomised women to either in-
duction of labour at 38 weeks’ gestation or 40 weeks’ gestation -
these intervention groups were not compared with an expectant
approach.
Studies awaiting classification
Two studies (Henry 1992; Dhaneshwor 2011 (CTRI/2011/12/
002290)) are awaiting classification. We contacted the trial authors
of the registered protocols of Dhaneshwor 2011 (CTRI/2011/12/
002290) to obtain information in relation to the study, including
the status of the study, the findings, and potential publications.
We contacted the contact author of Henry 1992 to obtain data
that related specifically to the women with gestational diabetes
in their study. We have yet to receive replies to our queries (see
Characteristics of studies awaiting classification).
Risk of bias in included studies
See and Figure 2 and Figure 3 for a summary of ’Risk of bias’
assessment.
16Planned birth at or near term for improving health outcomes for pregnant women with gestational diabetes and their infants (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
17Planned birth at or near term for improving health outcomes for pregnant women with gestational diabetes and their infants (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
We judged the study to be at low risk of bias for both sequence
generation and allocation concealment. The method of randomi-
sation was a computer-generated list and the list was blocked and
stratified by centre. Allocation concealment was achieved through
use of consecutively numbered, opaque, sealed envelopes.
Blinding
We judged Alberico 2017 to have a high risk of performance bias
given that it was not possible to blind either the women or health-
care professionals to the intervention of induction of labour. We
also judged the study to have a high risk of detection bias as the
authors report that women’s group assignment was indicated in
the paper questionnaire used for the initial reporting of data.
Incomplete outcome data
We grouped all maternal outcomes other than intact perineum and
considered Alberico 2017 to have a low risk of bias for attrition in
this instance. For the outcome intact perineum, data are available
for 94% of the women in the induction of labour group and 82%
of women in the expectant management group. Due to imbalances
in group attrition, we judged this to be of high risk of bias.
For hyperbilirubinaemia, data are available in the paper for 93%
of the newborn infants but it is not identified from which group
the missing infants are from. We contacted the authors about this
and in correspondence they indicated that data for 14 babies of
women in the induction of labour group and 14 in the expec-
tant management group were not available. Therefore, data on
this outcome are available for 93.45% of babies of women in the
induction of labour group and 92% in the expectant management
group. We therefore considered all neonatal outcomes as low risk
of bias for attrition bias.
Selective reporting
The published and registered protocol for Alberico 2017 is avail-
able (Maso 2011; NCT01058772). All outcomes stated in the
protocol, other than neonatal Apgar score at 10 minutes and uter-
ine rupture, are reported in the paper. (The study authors were
contacted and provided additional information in relation to uter-
ine rupture and Apgar scores at 10 minutes. They also provided
further information in relation to the group allocation for missing
data of neonatal hyperbilirubinaemia.)
Other potential sources of bias
We did not identify any additional potential sources of bias in
Alberico 2017 so therefore judged this to be of low risk of bias.
Effects of interventions
See: Summary of findings for the main comparison Planned
elective birth (induction or caesarean) compared to expectant
management for pregnant women with gestational diabetes
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Planned birth, at or near term, versus expectant




There was no clear difference between women randomised to in-
duction of labour and women randomised to expectant manage-
ment in:
1. maternal mortality or serious maternal morbidity (risk ratio
(RR) 1.48, 95% confidence interval (CI) 0.25 to 8.76, one trial,
425 women, Analysis 1.1);
2. caesarean section (RR 1.06, 95% CI 0.64 to 1.77, one trial,
425 women, Analysis 1.2);
3. instrumental vaginal birth (RR 0.81, 95% CI 0.45 to 1.46,
one trial, 425 women, Analysis 1.3).
For the primary outcome of maternal mortality or serious maternal
morbidity, there were no deaths in either group and no serious
maternal morbidity related to admissions to intensive care unit.
We assessed the quality of the evidence contributing to these out-
comes as very low, mainly due to high risk of bias of the included
study and imprecision of effect estimates (Summary of findings
for the main comparison).
Neonatal
There were no perinatal deaths in either group (Analysis 1.4) and
the quality of evidence for this outcome was judged as very low
mainly due to high risk of bias of the included study and im-
precision of effect estimates (Summary of findings for the main
comparison) There was no clear difference in infant outcomes be-
tween women randomised to induction of labour and women ran-
domised to expectant management in:
1. shoulder dystocia (RR 2.96, 95% CI 0.31 to 28.21, one
trial, 425 infants, Analysis 1.5, very low-quality evidence);
2. large-for-gestational age (RR 0.53, 95% CI 0.28 to 1.02,
one trial, 425 infants, Analysis 1.6, low-quality evidence)
(Summary of findings for the main comparison).
Secondary outcomes
Maternal
There were no maternal deaths in either group (Analysis 1.7).
There was no clear difference between women randomised to in-
duction of labour and women randomised to expectant manage-
ment in:
1. postpartum haemorrhage (RR 1.17, 95% CI 0.53 to 2.54,
one trial, 425 women, Analysis 1.11);
2. admission to intensive care unit (RR 1.48, 95% CI 0.25 to
8.76, one trial, 425 women, Analysis 1.8).
There was no clear difference between groups for the outcome
intact perineum (RR 1.02, 95% CI 0.73 to 1.43, one trial 373
women, Analysis 1.9). It should be noted that data in relation to
this outcome were available for 94% of women in the induction-
of-labour group and 82% of women in the expectant-management
group.
Uterine rupture was listed as a prespecified outcome in the pub-
lished and registered protocol of the Alberico study (Maso 2011;
NCT01058772), but not reported in the study findings. However,
we contacted the authors in relation to this and they informed
us that no woman participating in the study experienced uterine
rupture (Analysis 1.10).
Neonatal
No infant experienced birth trauma, therefore, we could not draw
conclusions about the effect of the intervention on the outcomes
of brachial plexus injury and bone fracture at birth (Analysis 1.12;
Analysis 1.13).
There was no clear difference in infant outcomes between women
randomised to induction of labour and women randomised to
expectant management in:
1. respiratory distress syndrome (RR 1.48, 95% CI 0.25 to
8.76, one trial, 425 infants, Analysis 1.14);
2. neonatal hypoglycaemia (RR 0.74, 95% CI 0.26 to 2.09,
one trial, 425 infants, Analysis 1.15);
3. and admission to neonatal intensive care unit (RR 0.99,
95% CI 0.14 to 6.94, one trial, 425 infants, Analysis 1.17).
Infants of women in the induction of labour group had higher inci-
dences of neonatal hyperbilirubinaemia when compared to infants
of women in the expectant management group (RR 2.46, 95%
CI 1.11 to 5.46, one trial, 397 infants, Analysis 1.16). However
it should be noted that the confidence interval is wide, suggesting
imprecision.
Outcomes not reported





3. Length of postnatal stay (mother)
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Infant
1. Acidaemia, intracranial haemorrhage
2. Hypoxia ischaemic encephalopathy
3. Small-for-gestational age
4. Length of postnatal stay (baby)
There was no information on cost reported by the Alberico 2017
study.
D I S C U S S I O N
Summary of main results
The aim of this review was to assess the effect of planned birth,
at or near term (37 to 40 weeks’ gestation) compared with an
expectant approach, for women with gestational diabetes. The
main outcomes relate to maternal and perinatal mortality and
morbidity. We included only one trial in this review; therefore, it
was not possible to conduct a meta-analysis.
The included study (Alberico 2017) evaluated maternal and peri-
natal outcomes after induction of labour versus expectant man-
agement in pregnant women with gestational diabetes at term. A
total of 425 women participated in this study, which the authors
acknowledge is underpowered for their primary outcome of cae-
sarean section. The authors of the study and of this review note
that the confidence intervals demonstrate a wide range, therefore
making it inappropriate to draw definite conclusions.
Maternal mortality or serious maternal morbidity or incidence of
perinatal mortality rates (perinatal deaths) were outcomes reported
in Alberico 2017. There were no maternal or perinatal deaths re-
ported in either group and no differences were found for serious
maternal morbidity, defined as admissions to intensive care unit.
There were also no differences between groups for caesarean sec-
tion or instrumental vaginal birth. The incidence of caesarean sec-
tion was 12.6% among women in the induction-of-labour group
and 11.8% in women in the expectant-management group. The
most common indications for caesarean section were non-reassur-
ing fetal heart monitoring (25% induction of labour group versus
48% expectant management group), mechanical dystocia, defined
as fetopelvic disproportion (33% induction of labour group ver-
sus 20% expectant management group), and dynamic dystocia,
defined as ’inadequate cervical dilation or fetal descent’ (29.6%
induction of labour group versus 12% expectant management
group). No clear differences were observed for other outcomes in
women such as postpartum haemorrhage or intact perineum.
The neonatal data recorded in the Alberico 2017 study iden-
tified a difference between infants of women in the induction
of labour group versus expectant management, for one outcome
- hyperbilirubinaemia. Infants of women in the induction-of-
labour group had higher incidences of neonatal hyperbilirubi-
naemia when compared to infants of women in the expectant man-
agement group.
No clear difference was noted in shoulder dystocia, with three
events of dystocia recorded in infants of women in the induction-
of-labour group (1.4%) and one in the expectant-management
group (0.5%). Two cases of shoulder dystocia were resolved by the
application of suprapubic pressure and the McRoberts manoeuvre.
In the remaining two cases, internal manoeuvres were required.
The allocation to induction of labour versus expectant manage-
ment group for the actions required to relieve shoulder dystocia,
is not reported.
Overall completeness and applicability of
evidence
Only one trial was included in this review. Therefore, it was not
possible to conduct a meta-analysis of data for any outcome and
there is insufficient evidence to assess the effect of planned birth, at
or near term (37 to 40 weeks’ gestation) for women with gestational
diabetes. The trial gives an indication of the range of outcomes
that have been measured to date.
The incidence of caesarean section in Alberico 2017 (12.6%
among women in the induction-of-labour group and 11.8% in
women in the expectant-management group) is generally lower
when compared to reported rates in the contemporary literature.
The authors of the study suggest that this might be because of their
criteria to exclude women experiencing major risk factors for cae-
sarean section (e.g. maternal disease, previous caesarean section,
fetal distress, estimated fetal weight of more than 4000 g).
Although Alberico 2017 is the only trial eligible for inclusion in
this review, it is underpowered, in spite of recruitment occurring
over a four-year period at eight different centres in three different
countries. One reason suggested for this is the difficulty associated
with the randomisation of women to a planned birth group rather
than women making an informed choice of planned or expectant
management. This should be considered in future research. The
lack of data on optimal interventions in relation to planned birth
for this population of women, the existence of guidelines informed
by retrospective studies, and the lack of clinical consensus on the
most appropriate care option (Maso 2011) highlight the impor-
tance of research focused on women with gestational diabetes.
Quality of the evidence
This review included only one trial with 425 women with gesta-
tional diabetes.
Overall, the risk of bias in the study was assessed as low (if outcomes
other than intact perineum are grouped for assessment of attrition
bias for maternal outcomes).
We used the GRADE approach to assess the quality of evidence.
All outcomes included in our Summary of findings for the main
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comparison, were downgraded for lack of blinding because it was
felt that knowledge of allocation could potentially affect the out-
comes. In addition, all outcomes were downgraded by two lev-
els for imprecision, other than large-for-gestational age which was
downgraded by one level. Of the seven outcomes included in our
Summary of findings for the main comparison, maternal mortal-
ity or serious maternal morbidity, caesarean section, instrumental
vaginal birth, perinatal mortality and shoulder dystocia were all
graded as very low-quality evidence. Large-for-gestational age was
graded as low-quality evidence and there were no data available
for acidaemia.
The Institute for Maternal and Child Health, IRCCS, Burlo
Garofolo offered “human and financial resources to carry out the
project” (Alberico 2017). The authors of the Alberico 2017 study
declared no conflict of interest.
Potential biases in the review process
This review was conducted in line with the guidance and proce-
dures outlined in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011), therefore minimising the introduc-
tion of bias during the review process. We undertook a compre-
hensive systematic search of databases and so are confident that all
relevant studies were identified. We attempted to minimise bias by
ensuring two review authors (LB and DD) independently assessed
all potential studies identified by the search for inclusion, judged
risk of bias, and extracted data.
Agreements and disagreements with other
studies or reviews
Our findings demonstrate that there is limited high-quality evi-
dence to inform decisions on the effectiveness of planned birth at
or near term gestation for women with gestational diabetes com-
pared with an expectant approach. This was also the case in the
conclusion of another review (Witkop 2009). The Witkop 2009
review included one randomised trial and four observational stud-
ies. While the findings of the Witkop 2009 review noted that
the included observational studies suggest a potential reduction in
macrosomia and shoulder dystocia with induction of labour and
planned caesarean birth, the trial included in the review (Henry
1992), demonstrated no clear difference in rates of caesarean birth,
shoulder dystocia, neonatal hypoglycaemia or perinatal deaths in
the outcomes for women in the induction of labour versus the
women in the expectant management group (Witkop 2009). It
should be noted that published data from the trial included in the
Witkop 2009 review does not differentiate between pre-existing
and gestational diabetes and therefore has been allocated to the
studies awaiting classification for this review (See Characteristics
of studies awaiting classification).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is limited evidence to inform implications for practice. Data
that are available are not of high quality and lack power to detect
possible important differences in either benefit or harm.
Implications for research
There is an urgent need for high-quality trials evaluating the effec-
tiveness of planned birth at or near term gestation for women with
gestational diabetes compared with an expectant approach. Given
the equipoise on optimal approach, researchers planning these tri-
als could consider strategies to optimise recruitment of women to
their studies. This could include strategies to explain clearly the
concept of equipoise with specific reference to the proposed study.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Alberico 2017
Methods Study design: multicentre open-labelled randomised controlled trial.
Duration of study: 4 years (recruitment phase).
Study dates: March 2010 - March 2014 (recruitment phase).
Participants Setting: 8 ’centres’ in 3 countries (Italy, Slovenia, Israel).
Inclusion criteria: pregnant women, older than 18, with singleton pregnancy, vertex
presentation and diagnoses of gestational diabetes in this pregnancy
Exclusion criteria: diagnosis of overt diabetes, prior caesarean section, obstetrical con-
traindications to vaginal delivery, maternal pregnancy-related disease or non-reassuring
fetal well-being necessitating prompt delivery, uncertain gestational age, known fetal
anomaly, Bishop score > 7, or estimated fetal weight of 4000 g at enrolment
Participants randomised (#): 425 women
(530 women were recruited, 59 women opted out and 46 women were not eligible)
Characteristics for planned subgroup analysis:
Parity: mixed. Both nulliparous and multiparous women included (% presented in Table
1 of manuscript). 125/214 (59.4%) nulliparous women in planned birth group versus
104/211 (49.3%) nulliparous women in expectant approach group. 87/214 (40.6%)
multiparous women in planned group versus 107/211 (50.7%) multiparous women in
the expectant approach group
Interventions Planned birth: N = 214 women. Between 38-39 weeks of gestation, women in this
group were admitted to the ward and induction of labour was performed
“IOL will be performed using dinoprostone, 2 mg vaginally, or dinoprostone, 0.5 mg
intracervically in 6-8 hours intervals (up to 5 doses) or dinoprostone 10 mg vaginal
device. Once the patient’s Bishop score exceeds 7 or regular contractions are diagnosed,
patients will be transferred to the delivery ward for artificial rupture of membranes or
oxytocin augmentation as indicated. Patients, in which cervical ripening does not occur
(Bishops score < 7) after 5 attempts with prostaglandin E2 (PGE2), will be offered
either oxytocin or Foley catheter induction or caesarean section, according to protocol”
(Published Protocol, Maso et al 2011:4)
2 women in this group (0.9%) presented with spontaneous onset of labour
Expectant approach: N = 211 women. Women enrolled in this group (between 38-39
weeks’ gestation) were followed up twice weekly by electronic fetal heart rate monitoring
and biophysical profile until 41 weeks’ gestation, when induction of labour was then
offered
“...patients enrolled in the conservative management arm will be followed up twice
weekly by Electronic Fetal Heart Rate monitoring and Biophysical Profile. Patients will
be followed up until 41 weeks’ gestation. Women, who do not deliver by this gestational
age, will be admitted for IOL. IOL will be offered when non-reassuring fetal status
is suspected. All patients in the conservative arm will undergo fetal weight ultrasound
estimation prior to IOL. Patients with estimated fetal weight of over 4000 g will be
offered a caesarean section” (Published Protocol, Maso et al 2011:4)
50 women in this group (23.7%) underwent induction of labour for “obstetric or medical
indications”
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Alberico 2017 (Continued)
Outcomes Outcomes considered in the review and reported in or extracted from the study:
outcome data for serious maternal morbidity, caesarean section, instrumental birth,
intact perineum, postpartum haemorrhage, admission to ICU, perinatal mortality rate,
shoulder dystocia, large-for-gestational age, birth trauma, respiratory distress syndrome,
neonatal hypoglycaemia, neonatal hyperbilirubinaemia, admission to NICU
Notes Funding: The Institute for Maternal & Child Health, IRCCS, Burlo Garofolo “offered
human and financial resources to carry out the project”
Trial authors’ declaration of interest: none declared.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomisation was centralised and coor-
dinated by the Clinical Epidemiology and
Biostatistics Unit (IRCCS) using a com-
puter based method. The randomisation
list was blocked and stratified by centre.”
Allocation concealment (selection bias) Low risk “The allocation concealment was guaran-
teed through the use of consecutively num-
bered and sealed opaque envelopes.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants: “The study was an open-label
trial because of the practical impossibility
to blind either healthcare professionals or
patients to the allocation group“
Personnel: “The study was an open-label
trial because of the practical impossibility
to blind either healthcare professionals or
patients to the allocation group“
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not stated explicitly but unlikely given fol-
lowing extract from study report
“General information on recruited pa-
tients, outcomes and randomization group
will be indicated in an appropriate paper
questionnaire in the first instance and then
reported on an electronic database acces-
sible from different study sites in the sec-
ond instance. In each participating centre,
medical personnel will fill up the electronic
form directly.“
Incomplete outcome data (attrition bias)
Maternal-perineum intact
High risk Outcome data available for all women ran-
domised (induction 214, expectant 211)
other than perineal trauma where data are
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Alberico 2017 (Continued)
available for 198/211, 94% (induction)
and 175/214, 82% (expectant)
Incomplete outcome data (attrition bias)
Maternal-all outcomes (other than intact
perineum)
Low risk Outcome data available for all women ran-
domised (induction 214, expectant 211)
other than perineal trauma where data are
available for 198/211, 94% (induction)
and 175/214, 82% (expectant)
Incomplete outcome data (attrition bias)
Neonatal-all outcomes
Low risk Outcome data available for all infants of
mothers randomised with exception of hy-
perbilirubinaemia, which is available for
93.45% of babies of women in the induc-
tion of labour group and 92% in the ex-
pectant management group
Selective reporting (reporting bias) Low risk Published and registered protocol available.
All outcomes stated in protocol other than
10-minute Apgar score and uterine rupture
reported in paper
Other bias Low risk No other obvious risk of bias identified.
ICU: intensive care unit
IOL: induction of labour
NICU: neonatal intensive care unit
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ghosh 1979 Focus: “Type B diabetes”.
No further details or publications in the intervening period (38 years)
Khojandi 1974 Insufficient information to determine randomisation.
Given that this study was published 42 years ago, we did not attempt to contact the authors
Worda 2017 This trial randomised women to either induction of labour at 38 weeks’ gestation or 40 weeks’ gestation - these
intervention groups were not compared with an expectation approach
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Characteristics of studies awaiting assessment [ordered by study ID]
Dhaneshwor 2011 (CTRI/2011/12/002290)
Methods Study design: “Randomised, parallel group, active controlled trial”.
Duration of the study: protocol registered (CTRI/2011/12/002290) on 26/12/2011.
Participants Setting: Vellore, Tamil Nadu.
Inclusion criteria: “Maternal age ? 18 years, willing for delivery at Christian Medical College (CMC) Vellore,
singleton pregnancy in vertex presentation, gestational age between 39+ and 40 weeks, by LMP sure of dates or by
early scan.”
Exclusion criteria: “Women not willing for delivery at CMC, Vellore, Prior C-section, suspected estimated fetal
weight of > 3.5 kg or any known contraindications to vaginal delivery, uncertain gestational age, non reassuring fetal
wellbeing necessitating delivery, maternal pregnancy-related disease necessitating delivery, known fetal anomaly”
Interventions Planned birth: “Induction group - for those in the induction group arm, cervical ripening will be done with
Misoprostol (25mcg every 6th hourly [sic] for 2 doses) as is the routine for induction of labour in our hospital. A 3rd
dose will be used if the cervix is still unfavourable and NST is reactive. If cervix remains unfavourable after 3 doses,
patient may be re-induced after 2-3 days as situation warrants or as per the parent treating unit protocol (PGE1
25mcg Q6h 2 dose)”
Expectant approach: “Expectant Group - for those allocated to expectant group, they will be followed up until
delivery, with AFI (amniotic fluid index) and NST (non stress test) twice a week. In absence of spontaneous delivery,
labour will be induced at 40+6 weeks. In presence of non-reassuring fetal well-being at one of the follow-ups, she
will immediately be offered labour induction”
Outcomes Outcomes considered relevant to this review: at time of birth: caesarean section, model of delivery, presence
of perineal tears, postpartum haemorrhage, shoulder dystocia, newborn birthweight, arterial cord pH. At time
of discharge: maternal or neonatal intensive care, maternal and perinatal death, neonatal birth trauma, neonatal
respiratory distress, neonatal hyperbilirubinaemia, neonatal hypoglycaemia
Notes Funding: not known.
Trial authors’ declaration of interest: none declared.
The authors were contacted on: 10th Jan 2017 (to obtain more information in relation to the study, including the
status of the study, findings and potential publications)
Henry 1992
Methods Study design: “Randomised Trial”.
Duration of the study: 3.5 years.
Participants Setting: Women’s Hospital, Los Angeles County - University of Southern California Medical Center
Inclusion criteria: “women diagnosed before pregnancy with insulin-dependent diabetes mellitus or non-insulin-
dependent diabetes mellitus without vascular complications or with gestational diabetes requiring insulin treatment
during pregnancy, and with good metabolic control of blood glucose levels ... 38 completed weeks’ gestation (266
days), good compliance with clinical appointments and home blood glucose monitoring, no abnormalities in the
twice weekly antepartum assessment with nonstress testing and amniotic fluid volume measurement performed from
34 weeks onward, singleton gestation and cephalic presentation, clinical and ultrasonographic estimation of fetal
weight <3800gm at 38 completed weeks with no evidence of intrauterine growth retardation, no other medical or
obstetric complications, a candidate for trial of vaginal delivery (no more than 2 previous C-sections)”
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Henry 1992 (Continued)
Interventions Planned birth: N = 100 women, “labour was induced with iv oxytocin .... in women with favourable Bishops Score
(<4), unscarred uteri and normal amniotic fluid indexes (>5.0cms), up to 3 applications of vaginal prostaglandin (3
mg) were used for cervical ripening before oxytocin treatment”
Expectant approach: N = 100 women, “expectant management consisted of daily split dose insulin therapy and
home blood glucose monitoring, weekly antenatal clinic visits, and twice-weekly antepartum testing”. Induction of
labour indicated by: “suspected fetal distress .... preeclampsia, maternal hyperglycaemia, estimated fetal weight >
4200gm, 42 weeks gestation”
Outcomes Outcomes considered relevant to this review: mode of delivery - vaginal delivery, caesarean delivery; infant birth-
weight - macrosomia, large-for-gestational age; infant outcome - shoulder dystocia, birth trauma (bone fracture, Erbs
palsy), hypoglycaemia, mortality
Notes Funding: not known.
Trial authors declaration of Interest: none declared.
The authors were contacted on: 10th Jan 2017 (to obtain data specifically related to women with gestational diabetes
in the planned birth versus expectant approach groups)
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D A T A A N D A N A L Y S E S
Comparison 1. Planned elective birth (induction or caesarean) versus expectant




participants Statistical method Effect size
1 Maternal mortality or serious
maternal morbidity
1 425 Risk Ratio (M-H, Fixed, 95% CI) 1.48 [0.25, 8.76]
2 Caesarean section 1 425 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.64, 1.77]
3 Instrumental vaginal birth 1 425 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.45, 1.46]
4 Perinatal mortality rate 1 425 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Shoulder dystocia 1 425 Risk Ratio (M-H, Fixed, 95% CI) 2.96 [0.31, 28.21]
6 Large-for-gestational age 1 425 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.28, 1.02]
7 Maternal death 1 425 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Admission to ICU 1 425 Risk Ratio (M-H, Fixed, 95% CI) 1.48 [0.25, 8.76]
9 Intact perineum 1 373 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.73, 1.43]
10 Uterine rupture 1 425 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Postpartum haemorrhage 1 425 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.53, 2.54]
12 Brachial plexus injury 1 425 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
13 Bone fracture at birth 1 425 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
14 Respiratory distress syndrome 1 425 Risk Ratio (M-H, Fixed, 95% CI) 1.48 [0.25, 8.76]
15 Neonatal hypoglycaemia 1 425 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.26, 2.09]
16 Neonatal hyperbilirubinaemia 1 397 Risk Ratio (M-H, Fixed, 95% CI) 2.46 [1.11, 5.46]
17 Admission to NICU 1 425 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.14, 6.94]
Analysis 1.1. Comparison 1 Planned elective birth (induction or caesarean) versus expectant, Outcome 1
Maternal mortality or serious maternal morbidity.
Review: Planned birth at or near term for improving health outcomes for pregnant women with gestational diabetes and their infants
Comparison: 1 Planned elective birth (induction or caesarean) versus expectant
Outcome: 1 Maternal mortality or serious maternal morbidity
Study or subgroup Planned Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Alberico 2017 (1) 3/214 2/211 100.0 % 1.48 [ 0.25, 8.76 ]
Total (95% CI) 214 211 100.0 % 1.48 [ 0.25, 8.76 ]
Total events: 3 (Planned), 2 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours planned Favours expectant
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(1) Serious maternal morbidity (admission to ICU)
Analysis 1.2. Comparison 1 Planned elective birth (induction or caesarean) versus expectant, Outcome 2
Caesarean section.
Review: Planned birth at or near term for improving health outcomes for pregnant women with gestational diabetes and their infants
Comparison: 1 Planned elective birth (induction or caesarean) versus expectant
Outcome: 2 Caesarean section
Study or subgroup Planned Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Alberico 2017 27/214 25/211 100.0 % 1.06 [ 0.64, 1.77 ]
Total (95% CI) 214 211 100.0 % 1.06 [ 0.64, 1.77 ]
Total events: 27 (Planned), 25 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours planned Favours expectant
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Analysis 1.3. Comparison 1 Planned elective birth (induction or caesarean) versus expectant, Outcome 3
Instrumental vaginal birth.
Review: Planned birth at or near term for improving health outcomes for pregnant women with gestational diabetes and their infants
Comparison: 1 Planned elective birth (induction or caesarean) versus expectant
Outcome: 3 Instrumental vaginal birth
Study or subgroup Planned Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Alberico 2017 18/214 22/211 100.0 % 0.81 [ 0.45, 1.46 ]
Total (95% CI) 214 211 100.0 % 0.81 [ 0.45, 1.46 ]
Total events: 18 (Planned), 22 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours planned Favours expectant
Analysis 1.4. Comparison 1 Planned elective birth (induction or caesarean) versus expectant, Outcome 4
Perinatal mortality rate.
Review: Planned birth at or near term for improving health outcomes for pregnant women with gestational diabetes and their infants
Comparison: 1 Planned elective birth (induction or caesarean) versus expectant
Outcome: 4 Perinatal mortality rate
Study or subgroup Planned Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Alberico 2017 0/214 0/211 Not estimable
Total (95% CI) 214 211 Not estimable
Total events: 0 (Planned), 0 (Expectant)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours planned Favours expectant
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Analysis 1.5. Comparison 1 Planned elective birth (induction or caesarean) versus expectant, Outcome 5
Shoulder dystocia.
Review: Planned birth at or near term for improving health outcomes for pregnant women with gestational diabetes and their infants
Comparison: 1 Planned elective birth (induction or caesarean) versus expectant
Outcome: 5 Shoulder dystocia
Study or subgroup Planned Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Alberico 2017 3/214 1/211 100.0 % 2.96 [ 0.31, 28.21 ]
Total (95% CI) 214 211 100.0 % 2.96 [ 0.31, 28.21 ]
Total events: 3 (Planned), 1 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours planned Favours expectant
Analysis 1.6. Comparison 1 Planned elective birth (induction or caesarean) versus expectant, Outcome 6
Large-for-gestational age.
Review: Planned birth at or near term for improving health outcomes for pregnant women with gestational diabetes and their infants
Comparison: 1 Planned elective birth (induction or caesarean) versus expectant
Outcome: 6 Large-for-gestational age
Study or subgroup Planned Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Alberico 2017 (1) 13/214 24/211 100.0 % 0.53 [ 0.28, 1.02 ]
Total (95% CI) 214 211 100.0 % 0.53 [ 0.28, 1.02 ]
Total events: 13 (Planned), 24 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 1.90 (P = 0.058)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours planned Favours expectant
(1) > or equal to 4000g
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Analysis 1.7. Comparison 1 Planned elective birth (induction or caesarean) versus expectant, Outcome 7
Maternal death.
Review: Planned birth at or near term for improving health outcomes for pregnant women with gestational diabetes and their infants
Comparison: 1 Planned elective birth (induction or caesarean) versus expectant
Outcome: 7 Maternal death
Study or subgroup Planned Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Alberico 2017 0/214 0/211 Not estimable
Total (95% CI) 214 211 Not estimable
Total events: 0 (Planned), 0 (Expectant)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours planned Favours expectant
Analysis 1.8. Comparison 1 Planned elective birth (induction or caesarean) versus expectant, Outcome 8
Admission to ICU.
Review: Planned birth at or near term for improving health outcomes for pregnant women with gestational diabetes and their infants
Comparison: 1 Planned elective birth (induction or caesarean) versus expectant
Outcome: 8 Admission to ICU
Study or subgroup Planned Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Alberico 2017 3/214 2/211 100.0 % 1.48 [ 0.25, 8.76 ]
Total (95% CI) 214 211 100.0 % 1.48 [ 0.25, 8.76 ]
Total events: 3 (Planned), 2 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours planned Favours expectant
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Analysis 1.9. Comparison 1 Planned elective birth (induction or caesarean) versus expectant, Outcome 9
Intact perineum.
Review: Planned birth at or near term for improving health outcomes for pregnant women with gestational diabetes and their infants
Comparison: 1 Planned elective birth (induction or caesarean) versus expectant
Outcome: 9 Intact perineum
Study or subgroup Planned Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Alberico 2017 53/198 46/175 100.0 % 1.02 [ 0.73, 1.43 ]
Total (95% CI) 198 175 100.0 % 1.02 [ 0.73, 1.43 ]
Total events: 53 (Planned), 46 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.92)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours planned Favours expectant
Analysis 1.10. Comparison 1 Planned elective birth (induction or caesarean) versus expectant, Outcome 10
Uterine rupture.
Review: Planned birth at or near term for improving health outcomes for pregnant women with gestational diabetes and their infants
Comparison: 1 Planned elective birth (induction or caesarean) versus expectant
Outcome: 10 Uterine rupture
Study or subgroup Planned Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Alberico 2017 0/214 0/211 Not estimable
Total (95% CI) 214 211 Not estimable
Total events: 0 (Planned), 0 (Expectant)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours planned Favours expectant
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Analysis 1.11. Comparison 1 Planned elective birth (induction or caesarean) versus expectant, Outcome 11
Postpartum haemorrhage.
Review: Planned birth at or near term for improving health outcomes for pregnant women with gestational diabetes and their infants
Comparison: 1 Planned elective birth (induction or caesarean) versus expectant
Outcome: 11 Postpartum haemorrhage
Study or subgroup Planned Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Alberico 2017 (1) 13/214 11/211 100.0 % 1.17 [ 0.53, 2.54 ]
Total (95% CI) 214 211 100.0 % 1.17 [ 0.53, 2.54 ]
Total events: 13 (Planned), 11 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.70)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours planned Favours expectant
(1) Defined as bleeding from the genital tract of 1000mls or more in the first 24 hours following the birth of the baby
Analysis 1.12. Comparison 1 Planned elective birth (induction or caesarean) versus expectant, Outcome 12
Brachial plexus injury.
Review: Planned birth at or near term for improving health outcomes for pregnant women with gestational diabetes and their infants
Comparison: 1 Planned elective birth (induction or caesarean) versus expectant
Outcome: 12 Brachial plexus injury
Study or subgroup Planned Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Alberico 2017 0/214 0/211 Not estimable
Total (95% CI) 214 211 Not estimable
Total events: 0 (Planned), 0 (Expectant)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours planned Favours expectant
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Analysis 1.13. Comparison 1 Planned elective birth (induction or caesarean) versus expectant, Outcome 13
Bone fracture at birth.
Review: Planned birth at or near term for improving health outcomes for pregnant women with gestational diabetes and their infants
Comparison: 1 Planned elective birth (induction or caesarean) versus expectant
Outcome: 13 Bone fracture at birth
Study or subgroup Planned Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Alberico 2017 0/214 0/211 Not estimable
Total (95% CI) 214 211 Not estimable
Total events: 0 (Planned), 0 (Expectant)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours planned Favours expectant
Analysis 1.14. Comparison 1 Planned elective birth (induction or caesarean) versus expectant, Outcome 14
Respiratory distress syndrome.
Review: Planned birth at or near term for improving health outcomes for pregnant women with gestational diabetes and their infants
Comparison: 1 Planned elective birth (induction or caesarean) versus expectant
Outcome: 14 Respiratory distress syndrome
Study or subgroup Planned Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Alberico 2017 3/214 2/211 100.0 % 1.48 [ 0.25, 8.76 ]
Total (95% CI) 214 211 100.0 % 1.48 [ 0.25, 8.76 ]
Total events: 3 (Planned), 2 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Not applicable
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Analysis 1.15. Comparison 1 Planned elective birth (induction or caesarean) versus expectant, Outcome 15
Neonatal hypoglycaemia.
Review: Planned birth at or near term for improving health outcomes for pregnant women with gestational diabetes and their infants
Comparison: 1 Planned elective birth (induction or caesarean) versus expectant
Outcome: 15 Neonatal hypoglycaemia
Study or subgroup Planned Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Alberico 2017 6/214 8/211 100.0 % 0.74 [ 0.26, 2.09 ]
Total (95% CI) 214 211 100.0 % 0.74 [ 0.26, 2.09 ]
Total events: 6 (Planned), 8 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Not applicable
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Analysis 1.16. Comparison 1 Planned elective birth (induction or caesarean) versus expectant, Outcome 16
Neonatal hyperbilirubinaemia.
Review: Planned birth at or near term for improving health outcomes for pregnant women with gestational diabetes and their infants
Comparison: 1 Planned elective birth (induction or caesarean) versus expectant
Outcome: 16 Neonatal hyperbilirubinaemia
Study or subgroup Planned Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Alberico 2017 20/200 8/197 100.0 % 2.46 [ 1.11, 5.46 ]
Total (95% CI) 200 197 100.0 % 2.46 [ 1.11, 5.46 ]
Total events: 20 (Planned), 8 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 2.22 (P = 0.026)
Test for subgroup differences: Not applicable
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Analysis 1.17. Comparison 1 Planned elective birth (induction or caesarean) versus expectant, Outcome 17
Admission to NICU.
Review: Planned birth at or near term for improving health outcomes for pregnant women with gestational diabetes and their infants
Comparison: 1 Planned elective birth (induction or caesarean) versus expectant
Outcome: 17 Admission to NICU
Study or subgroup Planned Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Alberico 2017 2/214 2/211 100.0 % 0.99 [ 0.14, 6.94 ]
Total (95% CI) 214 211 100.0 % 0.99 [ 0.14, 6.94 ]
Total events: 2 (Planned), 2 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. Search terms for ICTRP and ClinicalTrials.gov
ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform.
WHO International Clinical Trials Registry Platform (ICTRP)




planned AND birth AND GDM
planned AND birth AND diabetes
planned AND birth AND diabetic
elective AND birth AND GDM
elective AND birth AND diabetes
elective AND birth AND diabetic
induction AND labo(u)r AND diabetes
induction AND labo(u)r AND GDM
Induction AND labo(u)r AND diabetic
expectant AND birth AND GDM
expectant AND birth AND diabetic
expectant AND birth AND diabetes
ClinicalTrials.gov
(we ran each search separately)
Advanced search
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1.
diabetes OR diabetic OR GDM - Condition
cesarean OR caesarean - Intervention
2.
diabetic OR diabetes OR GDM - Condition
(planned OR elective OR expectant) AND (birth OR delivery) - Intervention
3.
diabetes OR diabetic OR GDM - Condition
induction AND (labour OR labor)
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D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
The title has changed from ’Planned elective birth at or near term for improving health outcomes for pregnant women with gestational
diabetes’, to ’Planned birth at or near term for improving health outcomes for pregnant women with gestational diabetes and their
infants’.
The protocol for this Cochrane review was published in PROSPERO on 16 August 2017 - see http://www.crd.york.ac.uk/PROSPERO/
display record.asp?ID=CRD42017072476. The protocol was not published in theCochrane Library.
N O T E S
The original review ’Elective delivery in diabetic pregnant women’ (Boulvain 2001) has now been split into two reviews.
• Planned birth at or near term for improving health outcomes for pregnant women with gestational diabetes and their infants
(this review).
• Planned birth at or near term for improving health outcomes for pregnant women with pre-existing diabetes and their infants
(Biesty 2017a).
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Diabetes, Gestational; ∗Term Birth; ∗Watchful Waiting; Cesarean Section; Fetal Macrosomia [∗prevention & control]; Labor, Induced
[∗methods]
MeSH check words
Female; Humans; Infant; Pregnancy
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